Who it's for
Built for the people who have to pick.
Where R&D compounds, and when to stop.
For CTOs, innovation leaders, corporate venture teams, and product strategists: estimated improvement rates to rank the R&D portfolio, benchmark internal progress against the outside world, scout the startups that could reshape your system, and decide when and where to build, invest, buy, partner or stop.
Semiconductors, quantum computing, energy, materials, chemicals, automotive, industrial robotics, aerospace. The method applies to any technology domain that can be defined.
Portfolio optimization
Benchmark each internal program against external domain rates. Then accelerate, partner or re-scope with a number in hand.
Build, buy, or partner
Combine domain trajectory with patent, inventor, and assignee signal to decide which capability should be internal, acquired, or accessed.
Scouting deep tech
Which emerging approaches are on a slope that will matter to your roadmap, and which to partner with, license, or acquire before they are obvious.
Where TechNext fits
The decisions where a rate pays for itself.
Meaningful allocationYour organization allocates capital, R&D, procurement, policy, or risk capacity across technology options.
Concentrated downsideIf the technology, the architecture or the timing is wrong, it hurts.
Pre-commercial evidenceThe technology is too early for revenue or unit-cost data, so the current process leans on expert opinion, roadmaps, trend labels, or raw patent counts.
Also on the desk
M&A and bankingWe pressure-test the technology story under a deal and map the patents, inventors, and assignees that can surface strategic targets before they become consensus.
Pensions and sovereign allocatorsAn independent check on technical assumptions at the horizon the institution owns.
Insurance and emerging riskDated capability thresholds with uncertainty bounds, so emerging-risk underwriting has something to monitor and price.
